MB21D2
MB21D2 (Nucleotidyltransferase MB21D2) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Head and neck squamous cell carcinoma, Sarcomas, Bladder & urothelial cancer and 2 more.
Overview
Probable nucleotidyltransferase that catalyses the formation of cyclic dinucleotide second messenger in response to some unknown stimulus.
IntOGen calls it a driver in 4 cohorts (1 activating, 3 loss-of-function), covering Head and Neck Squamous Cell Carcinoma, Liposarcoma, Lung Squamous Cell Carcinoma, Upper Tract Urothelial Carcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · MB21D2 (Nucleotidyltransferase MB21D2) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Head and neck squamous cell carcinoma, Sarcomas, Bladder & urothelial cancer and 2 more.
- 1 · What it is
MB21D2 (Nucleotidyltransferase MB21D2) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Head and neck squamous cell carcinoma, Sarcomas, Bladder & urothelial cancer and 2 more.
- 2 · What goes wrong in cancer
Probable nucleotidyltransferase that catalyses the formation of cyclic dinucleotide second messenger in response to some unknown stimulus. Locus 3q29 (HGNC).
- 3 · How drugs use it
No product in this corpus aims at MB21D2 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
External identifiers
Sources: HGNC HGNC:30438 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q8IYB1 (protein name, function text, keywords and locations (REST API)); IntOGen MB21D2 (driver in 4 cohorts (Act 1, LoF 3); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Probable nucleotidyltransferase that catalyses the formation of cyclic dinucleotide second messenger in response to some unknown stimulus. Locus 3q29 (HGNC).
- Head and neck squamous cell carcinoma: IntOGen driver in 1 cohort (HNSC)
- Sarcomas: IntOGen driver in 1 cohort (LIPO)
- Bladder & urothelial cancer: IntOGen driver in 1 cohort (UTUC)
- Liposarcoma: IntOGen driver in 1 cohort (LIPO)
- Non-small-cell lung cancer: IntOGen driver in 1 cohort (LUSC)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 3 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"MB21D2" OR ABSTRACT:"MB21D2" OR TITLE:"Mab-21 domain containing 2" OR ABSTRACT:"Mab-21 domain containing 2" OR TITLE:"Nucleotidyltransferase MB21D2" OR ABSTRACT:"Nucleotidyltransferase MB21D2" OR TITLE:"D2A" OR ABSTRACT:"D2A" OR TITLE:"C3orf59" OR ABSTRACT:"C3orf59") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MB21D2, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetACSL6
Shares Liposarcoma, Sarcomas (soft tissue, bone, GIST), IntOGen.
- TargetDDIT3
- TargetFUS
Shares Liposarcoma, Sarcomas (soft tissue, bone, GIST), IntOGen.
- TrialAPG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
- TechnologyMDM2 inhibitors
- TrialSpearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
- PersonPatrick Schöffski
- TrialSTRASS (EORTC 62092)